As the tiny Norwegian biotech gears up to put its first asset into the clinic, investors could use an ongoing trial to handicap its chances of success.
The two companies disagree on the commercial potential of an mRNA flu vaccine, and Biontech just got Pfizer’s buy-in.
Drug discovery is getting harder, and some companies are turning to machine learning to look for new targets.
Novo Nordisk's cell therapy collaborations are a sign that serious work is under way.
Japanese group prefers M&A over license
Axovant's need to rebuild its pipeline is benefiting gene therapy developers.
Private drug developers raised a record $8.5bn in the first half of 2018, amid a surge in mega rounds.